ARVN Arvinas, Inc.
Distress ·
Arvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends.
The company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs.
Arvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan.
Under the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $262.6 million | $263.4 million |
| Research and development | $285.2 million | $348.2 million |
| Net income (loss) | -$80.8 million | -$198.9 million |
| Cash from operations | -$273.8 million | -$259.3 million |
| Cash and equivalents | $142.9 million | $100.5 million |
| Short-term investments | $542.5 million | $938.9 million |
Our latest story on this, dated Sep 17, 2025: "Arvinas cuts about 15% of staff, authorizes $100 million buyback". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 17, 2025: "Arvinas to cut about 15% of staff, seek vepdegestrant partner; approves $100 million buyback". The story links the filing or release it is based on. Read the story.
Arvinas, Inc. trades under the ticker ARVN on NASDAQ.
Arvinas, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Arvinas, Inc. is 1655759. Its filings are on SEC EDGAR.
65,386,191 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Arvinas, Inc. under United States.
Our directory classifies Arvinas, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Arvinas, Inc. is US04335A1051.
aibio.space lists Arvinas, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$262.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Arvinas, Inc. reported a net loss of $80.8 million for the fiscal year ended Dec 31, 2025, and used $273.8 million of cash in operations, per its annual report to the SEC.
$285.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$567.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio